RIPPLE

**RIPPLE COMMENT** According to CBC News (established source), a 20-year-old Canadian medical paper is under renewed scrutiny for its claim that a baby died from opioid poisoning through breast milk. This controversy has sparked a re-examination of global approaches to pain management and breastfeeding guidance. The causal chain begins with the publication of this paper, which led to a widespread shift in pain management practices among healthcare providers. The direct cause-effect relationship is as follows: the paper's findings → increased use of alternative pain management methods for new mothers → reduced reliance on opioids like codeine during breastfeeding. Intermediate steps include changes in medical guidelines and recommendations from professional organizations. In the short term, this renewed scrutiny may lead to a re-evaluation of existing pain management protocols in Canadian clinics, potentially resulting in more conservative prescribing practices for opioids. In the long term, this could contribute to a decrease in opioid-related complications during breastfeeding and an improvement in overall maternal health outcomes. The domains affected by this news event include: * Healthcare: Pain Management Clinics * Public Health: Maternal and Child Health Evidence Type: Event Report (20-year-old medical paper under renewed scrutiny) Uncertainty: This could lead to a shift in pain management practices, but the extent of the change is uncertain. Depending on the outcome of ongoing reviews and updates to medical guidelines, the impact on opioid use during breastfeeding may be significant or minor.

**RIPPLE COMMENT** According to Science Daily (recognized source, 70/100 credibility tier), researchers have discovered a protein called HIF1 that may be the missing link behind painful tendon injuries like jumper's knee and tennis elbow. The mechanism by which this event affects pain management clinics is as follows: High levels of HIF1 cause harmful changes in tendons, making them brittle and prone to pain. This direct cause → effect relationship leads to an increase in the number of patients seeking treatment for these conditions. As a result, pain management clinics may experience an influx of new patients, placing additional strain on resources. Intermediate steps in this causal chain include: * Clinics increasing staff and equipment to meet demand (short-term effect) * Developing new treatments or therapies targeting HIF1 (long-term effect) This discovery impacts the following civic domains: healthcare, specialized care, pain management clinics, medical research. The evidence type is a research study. While this finding holds promise for improving treatment outcomes, its translation into clinical practice depends on further studies and regulatory approvals. Uncertainty surrounds the extent to which HIF1 inhibition will be effective in preventing tendon injuries and the potential side effects of targeting this protein. If further research confirms these findings, pain management clinics may need to adapt their services and develop new protocols for treating patients with tendon injuries.

**RIPPLE Comment** According to Financial Post (established source), Axsome Therapeutics has initiated the FORWARD Phase 3 trial of AXS-14 for the management of fibromyalgia, with the first patient dosed on January 15, 2026. The initiation of this clinical trial is a direct cause that could lead to an increase in the availability and effectiveness of treatments for fibromyalgia. If successful, the trial will provide evidence supporting the use of AXS-14 as a treatment option for patients with fibromyalgia. This, in turn, may lead to an expansion of pain management clinics' treatment options, potentially improving patient outcomes and quality of life. In the short-term (2026-2028), this could result in increased demand for healthcare professionals trained in pain management, particularly those specializing in fibromyalgia care. In the long-term (2029 and beyond), successful trial outcomes may lead to changes in clinical guidelines and reimbursement policies, further increasing access to effective treatments. The domains affected by this news event include: * Healthcare: specialized care, pain management clinics * Biotechnology: CNS disorder treatment research Evidence Type: Event Report (initiation of a clinical trial) Uncertainty: This could lead to improved patient outcomes if the trial is successful and AXS-14 proves effective. However, there are uncertainties surrounding the trial's outcome, including potential side effects or efficacy limitations. --- Source: [Financial Post](https://financialpost.com/globe-newswire/axsome-therapeutics-initiates-forward-phase-3-trial-of-axs-14-for-the-management-of-fibromyalgia) (established source, credibility: 90/100)